Your browser does not support iframes.
Schizophrenia affects 24 million people. Antipsychotics are generally effective for the treatment of Schizophrenia, however there is a critical unmet need: 75% of patients are non-adherent to treatment within 2 years. Moreover, the relapse rate is 2-5 times higher in non-adherent patients. The economic burden of relapses and re-hospitalizations in US alone is $63B.Long-acting Injectable antipsychotics improve adherence but have significant limitations. Risperidone is the most frequently prescribed atypical antipsychotic. Existing long-acting formulations require frequent clinic visits (every two weeks), intramuscular injections to the buttock, and must be prepared using 17 reconstitution steps.Our current NTE LAI antipsychotic program is Risperidone LAI, which we are developing for delivery once every three months. This is based on an innovative proprietary technology that enables an extended-release of the medicine by means of a subcutaneous injection. We believe this will provide a product with the following characteristics: